The Australian body is the TGA and they can require clinical trials of a number of years. Manufacturers normally carry out clinical trials in various countries at the same time. Orphan drugs, drugs that have only a small demand, are treated differently in the US, EU and Australia. The US has the shortest lead time compared to the EU and Australia which may give the rubber stamp impression.